As of January 22, 2025, Cellectis S.A. (ALCLS.PA) has a market cap of $0.16 billion USD. According to our data, Cellectis S.A. is ranked No.7310 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.16 B |
-5.51%
|
Dec 31, 2024 | $0.17 B |
-41.03%
|
Dec 29, 2023 | $0.29 B |
39.10%
|
Dec 30, 2022 | $0.21 B |
-73.29%
|
Dec 31, 2021 | $0.78 B |
-69.51%
|
Dec 31, 2020 | $2.55 B |
55.61%
|
Dec 31, 2019 | $1.64 B |
3.98%
|
Dec 31, 2018 | $1.57 B |
-36.74%
|
Dec 29, 2017 | $2.49 B |
47.07%
|
Dec 30, 2016 | $1.69 B |
-42.21%
|
Dec 30, 2015 | $2.93 B |
129.35%
|
Dec 31, 2014 | $1.28 B |
431.74%
|
Dec 31, 2013 | $0.24 B |
-66.91%
|
Dec 28, 2012 | $0.72 B |
9.79%
|
Dec 30, 2011 | $0.66 B |
-12.08%
|
Dec 30, 2010 | $0.75 B |
-30.50%
|
Dec 31, 2009 | $1.08 B |
49.06%
|
Dec 31, 2008 | $0.72 B |
-22.78%
|
Dec 31, 2007 | $0.94 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.03 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.23 B |
-0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.00 B |
-0.030 B
|
USA
|
bluebird bio
BLUE
|
$77.02 M |
0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
-0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$36.21 M |
-0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Verve Therapeutics
VERV
|
$0.59 B |
-0.000 M
|
USA
|
Sana Biotechnology
SANA
|
$0.78 B |
-0.000 M
|
USA
|
Market Cap | = | ALCLS.PA Stock Price | * | ALCLS.PA Shares Outstanding |
= | $1.59 | * | 0.10 B | |
= | $0.16 B |